New Microsoft Price Target After a Quarter With ‘a Lot to Like’
Here’s why we’re gladly back in this Mag 7 name.
Here’s why we’re gladly back in this Mag 7 name.
I’ve got two biopharma stocks on my radar ahead of earnings.
Wall Street is treating AI like one crowded trade, but the companies building its future have very different risks—and very different potential.
We took profits early. Now we’re cutting further. It’s not about belief. It’s about what the charts are saying now.
The 30-year yield hit a 19-year high, and the earnings reports split the hyperscalers.
The Semiconductor stocks remain oversold and getting worse. Could the bank stocks be next?
The former Raytheon seems likely to follow General Dynamics higher.
Yesterday’s problem was the chips. Today’s problem with interest rates affects everyone. Here’s how I’m handling my trading.
The financial services firm has taken a turn for the worse.
Rising production and improving margin prospects have us bullish on BA; also, let’s connect the dots to ETN.